

Supplementary Online Content

Zissimopoulos JM, Barthold D, Brinton RD, Joyce G. Sex and race differences in the association between statin use and incidence of Alzheimer disease. *JAMA Neurol*. doi:10.1001/jamaneurol.2016.3783

eTable 1. Hazard Ratios (With *P* Values) of AD Incidence Associated With High Exposure to Statins in 2006-2008, Relative to Those With No Use 2006-2012

eTable 2. Hazard Ratios (With *P* Values) of AD Incidence Associated With High Statin Exposure, Relative to Low Exposure, in Sample Restricted to Individuals Observed 2006-2013

eTable 3. Hazard Ratios (With *P* Values) of AD Incidence Associated With High Statin Exposure, Relative to Low Exposure, in Sample Restricted to Users in 50th Percentile or Higher

eTable 4. Hazard Ratios (With *P* values) of AD Incidence in Years 2012-2013 Only, Associated With High Statin Exposure in 2006-2008, Relative to Low Exposure

eTable 5. Hazard Ratios (With *P* Values) of AD Incidence Associated With High Statin Exposure for Different Thresholds Defining High Statin Exposure, Relative to Low Exposures

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1: Hazard Ratios (With *P* Values) of AD Incidence Associated With High Exposure to Statins in 2006-2008, Relative to Those With No Use 2006-2012

	Female				Male			
	All	White	Hispanic	Black	All	White	Hispanic	Black
All	0.793	0.789	0.821	0.817	0.786	0.777	0.870	0.806
	p<0.001	p<0.001	p<0.001	p<0.001	p<0.001	p<0.001	p=0.086	p=0.015
Simvastatin	0.800	0.801	0.827	0.769	0.812	0.797	0.879	0.887
	p<0.001	p<0.001	p<0.001	p<0.001	p<0.001	p<0.001	p=0.230	p=0.303
Atorvastatin	0.788	0.784	0.792	0.863	0.780	0.773	0.836	0.816
	p<0.001	p<0.001	p=0.003	p=0.043	p<0.001	p<0.001	p=0.150	p=0.146
Pravastatin	0.753	0.745	0.746	0.911	0.741	0.744	0.639	0.862
	p<0.001	p<0.001	p=0.103	p=0.573	p<0.001	p=0.001	p=0.212	p=0.644
Rosuvastatin	0.770	0.723	1.024	0.796	0.693	0.630	1.162	1.008
	p<0.001	p<0.001	p=0.862	p=0.225	p<0.001	p<0.001	p=0.503	p=0.980

Hazard ratios, depicting relative risk of AD incidence during 2009-2013 for those with any exposure to statins, compared to no exposure. Individuals with high statin exposure are those with at least two days of filled prescriptions in the 50th percentile or higher of days of use per year in at least 1 of the 3 years from 2006 to 2008. The comparison groups did not use statins from 2006 to 2012.

eTable 2: Hazard Ratios (With *P* Values) of AD Incidence Associated With High Statin Exposure, Relative to Low Exposure, in Sample Restricted to Individuals Observed 2006-2013

	Female				Male			
	All	White	Hispanic	Black	All	White	Hispanic	Black
All	0.863	0.867	0.928	0.817	0.840	0.839	0.681	0.958
	p<0.001	p<0.001	p=0.327	p=0.004	p<0.001	p<0.001	p=0.003	p=0.757
Simvastatin	0.864	0.871	0.870	0.809	0.868	0.896	0.723	0.801
	p<0.001	p<0.001	p=0.210	p=0.047	p=0.007	p=0.059	p=0.073	p=0.307
Atorvastatin	0.825	0.836	0.874	0.842	0.820	0.815	0.676	0.867
	p<0.001	p<0.001	p=0.307	p=0.134	p<0.001	p=0.001	p=0.071	p=0.521
Pravastatin	0.835	0.797	0.963	0.892	0.782	0.821	0.628	0.751
	p=0.032	p=0.016	p=0.893	p=0.713	p=0.057	p=0.157	p=0.386	p=0.642
Rosuvastatin	0.901	0.900	1.393	0.654	0.805	0.821	0.476	2.740
	p=0.263	p=0.333	p=0.167	p=0.273	p=0.179	p=0.274	p=0.218	p=0.118

Hazard ratios, depicting relative risk of AD incidence during 2009-2013 for those with high exposure to statins, compared to low exposure. Individuals with high statin exposure are those with days of filled prescriptions in the 50th percentile or higher of use per year in at least 2 of the 3 years from 2006 to 2008. The low exposure group used the designated statin, but for fewer days, or later in the sample period.

eTable 3: Hazard Ratios (With *P* Values) of AD Incidence Associated With High Statin Exposure, Relative to Low Exposure, in Sample Restricted to Users in 50th Percentile or Higher

	Female				Male			
	All	White	Hispanic	Black	All	White	Hispanic	Black
All	0.834	0.847	0.803	0.773	0.877	0.892	0.680	0.857
	p<0.001	p<0.001	p=0.002	p<0.001	p<0.001	p=0.001	p=0.001	p=0.201
Simvastatin	0.836	0.860	0.724	0.771	0.898	0.921	0.731	0.748
	p<0.001	p<0.001	p=0.002	p=0.005	p=0.019	p=0.111	p=0.053	p=0.103
Atorvastatin	0.835	0.876	0.629	0.739	0.969	0.968	0.682	1.080
	p<0.001	p=0.002	p=0.002	p=0.010	p=0.599	p=0.625	p=0.110	p=0.759
Pravastatin	0.882	0.888	0.841	0.666	0.803	0.856	0.672	0.707
	p=0.101	p=0.160	p=0.552	p=0.171	p=0.065	p=0.224	p=0.424	p=0.531
Rosuvastatin	0.850	0.837	1.053	0.649	0.900	0.882	0.847	2.319
	p=0.067	p=0.087	p=0.816	p=0.203	p=0.446	p=0.427	p=0.658	p=0.227

Hazard ratios, depicting relative risk of AD incidence during 2009-2013 for those with high exposure to statins, compared to low exposure. Individuals with high statin exposure are those with days of filled prescriptions in the 50th percentile or higher of days of use per year in at least 2 of the 3 years from 2006 to 2008. The low exposure group used the same quantity of the same statin, in 2009, 2010, 2011, or 2012.

eTable 4: Hazard Ratios (With *P* Values) of AD Incidence in Years 2012-2013 Only, Associated With High Statin Exposure in 2006-2008, Relative to Low Exposure

	Female	Male
	All	All
All	0.866	0.901
	p<0.001	p=0.037
Simvastatin	0.893	0.907
	p=0.023	p=0.191
Atorvastatin	0.810	0.949
	p<0.001	p=0.494
Pravastatin	0.720	0.804
	p=0.013	p=0.238
Rosuvastatin	0.754	0.636
	p=0.055	p=0.103

Hazard ratios, depicting relative risk of AD incidence during 2012-2013 for those with high exposure to statins, compared to low exposure. Individuals with high statin exposure are those with days of filled prescriptions in the 50th percentile or higher of days of use per year in at least 2 of the 3 years from 2006 to 2008. The low exposure group used the designated statin, but for fewer days, or later in the sample period. Sample restricted to those observed 2006-2012.

eTable 5: Hazard Ratios (With *P* Values) of AD Incidence Associated With High Statin Exposure for Different Thresholds Defining High Statin Exposure, Relative to Low Exposures

	Female				Male			
	All	White	Hispanic	Black	All	White	Hispanic	Black
All Statins								
25th %	0.896	0.911	0.942	0.786	0.897	0.902	0.884	0.856
	p<0.001	p<0.001	p=0.316	p=0.708	p<0.001	p=0.002	p=0.188	p=0.136
50th %	0.854	0.856	0.880	0.817	0.875	0.891	0.710	0.858
	p<0.001	p<0.001	p=0.059	p<0.001	p<0.001	p<0.001	p=0.001	p=0.176
75th %	0.830	0.832	0.886	0.795	0.805	0.825	0.605	0.823
	p<0.001	p<0.001	p=0.128	p=0.001	p<0.001	p<0.001	p<0.001	p=0.134
Simvastatin								
25th %	0.873	0.881	0.886	0.794	0.893	0.901	0.811	0.866
	p<0.001	p<0.001	p=0.103	p=0.001	p=0.002	p=0.013	p=0.061	p=0.270
50th %	0.850	0.862	0.820	0.782	0.867	0.896	0.670	0.768
	p<0.001	p<0.001	p=0.043	p=0.005	p=0.001	p=0.024	p=0.009	p=0.122
75th %	0.825	0.839	0.798	0.747	0.807	0.831	0.507	0.777
	p<0.001	p<0.001	p=0.066	p=0.008	p<0.001	p=0.001	p=0.001	p=0.221
Atorvastatin								
25th %	0.890	0.902	0.936	0.883	0.936	0.946	0.846	0.892
	p<0.001	p=0.001	p=0.474	p=0.119	p=0.127	p=0.258	p=0.237	p=0.492
50th %	0.824	0.835	0.759	0.810	0.901	0.922	0.612	0.915
	p<0.001	p<0.001	p=0.024	p=0.030	p=0.024	p=0.113	p=0.009	p=0.640
75th %	0.794	0.807	0.724	0.798	0.821	0.862	0.462	0.852
	p<0.001	p<0.001	p=0.028	p=0.055	p<0.001	p=0.010	p=0.002	p=0.481
Pravastatin								
25th %	0.862	0.860	0.919	0.868	0.875	0.900	0.905	0.804
	p=0.011	p=0.021	p=0.677	p=0.479	p=0.146	p=0.293	p=0.785	p=0.569
50th %	0.821	0.816	0.818	0.756	0.779	0.823	0.748	0.702
	p=0.006	p=0.011	p=0.460	p=0.327	p=0.026	p=0.106	p=0.539	p=0.498
75th %	0.783	0.772	0.940	0.710	0.683	0.720	0.683	0.543

	p=0.00 5	p=0.00 7	p=0.845	p=0.37 3	p=0.00 5	p=0.02 3	p=0.528	p=0.40 0
Rosuvastatin								
25th %	0.921	0.934	0.950	0.790	0.852	0.851	0.821	1.149
	p=0.16 7	p=0.33 0	p=0.736	p=0.24 3	p=0.10 2	p=0.15 8	p=0.444	p=0.73 9
50th %	0.828	0.810	1.172	0.671	0.898	0.879	0.998	1.530
	p=0.02 3	p=0.03 1	p=0.440	p=0.21 7	p=0.40 4	p=0.38 1	p=0.996	p=0.42 3
75th %	0.757	0.762	1.146	0.337	0.827	0.840	1.081	1.134
	p=0.00 9	p=0.02 5	p=0.623	p=0.06 2	p=0.23 3	p=0.32 7	p=0.858	p=0.86 4

Hazard ratios, depicting relative risk of AD incidence during 2009-2013 for those with the designated exposure to statins, compared to lower exposure. Individuals with high statin exposure are those with days of filled prescriptions in the 25th, 50th, or 75th percentile of higher of days of use per year in at least 2 of the 3 years from 2006 to 2008. The low exposure group used the designated statin, but for fewer days, or later in the sample period.